Researchers from Karolinska Institute in Sweden published a paper in the latest issue of Frontier Journal of Immunology, pointing out that the level of cytokines interleukin 26 (IL-26) in the blood of patients with acute COVID-19 infection increased, and the high level of IL-26 was related to the increased degree of inflammatory reaction, which meant that the symptoms were more serious. These findings suggest that IL-26 is a potential biomarker of severe COVID-19. It has been proved that COVID-19 vaccination can effectively reduce the number of severe patients with COVID-19. However, as new virus variants continue to appear, the number of vaccinations is insufficient and human immunity declines, scientists begin to look for more effective COVID-19 therapy. Eduardo Cadnias, the main author of the latest study and postdoctoral fellow of the Institute of Environmental Medicine, said: "We need to better understand the potential immune mechanism in order to find better treatment methods. In addition, we need to improve the diagnostic efficiency of patients with COVID-19." Anders Linde, another author of the study, said: "We have known that the cytokine IL-26 is involved in mobilizing immune cells to fight against pulmonary bacterial infections and human chronic respiratory diseases. More importantly, IL-26 has antiviral and antibacterial effects." In order to study the "role" of this molecule in COVID-19 infection, the research team recruited 49 hospitalized patients with COVID-19, 44 of whom were severely ill and needed oxygen therapy. At the same time, 27 healthy people were recruited as the control group, and the levels of IL-26 protein and other inflammatory compounds in the blood of all participants were measured. Cadnias said: "Our research shows for the first time that the level of cytokines IL-26 in the blood of patients with COVID-19 is much higher than that of healthy controls. This increase is related to the so-called cytokine storm, which is an excessive and dangerous inflammatory reaction, indicating the severity of COVID-19. The latest findings provide us with a potential biomarker for the severity of COVID-19. Moreover, in view of the antiviral effect of IL-26, we may also determine that New therapeutic targets. " However, the research team also said that although the latest research results are promising, it is still a preliminary study. They are conducting a larger study to obtain more information, such as whether the level of IL-26 can reflect the severity of COVID-19. (Outlook New Times)
Edit：qihang Responsible editor：xinglan
Source：http://digitalpaper.stdaily.com/
Special statement: if the pictures and texts reproduced or quoted on this site infringe your legitimate rights and interests, please contact this site, and this site will correct and delete them in time. For copyright issues and website cooperation, please contact through outlook new era email：lwxsd@liaowanghn.com
Recommended Reading Change it 
Home
